Core Viewpoint - Vivos Therapeutics, Inc. has announced that a recent study supports its belief that dental and facial morphology is directly correlated to the prevalence and severity of obstructive sleep apnea (OSA) in both adults and children [1][3]. Company Overview - Vivos Therapeutics, Inc. is a medical technology company focused on developing and commercializing innovative diagnostic and treatment methods for patients suffering from breathing and sleep issues related to dentofacial abnormalities such as OSA and snoring [9]. - The company’s CARE devices have received FDA clearance for treating all severity levels of OSA in adults and moderate-to-severe OSA in children aged 6 to 17 [9]. Study Findings - The study titled "Correlation Between Severity of Obstructive Sleep Apnea and Dental Arch Form in Adults" indicates that small changes in dental and jaw morphology can lead to significant changes in airway function, with narrower intermolar distance and greater palatal height linked to higher Apnea-Hypopnea Index (AHI) [3][4]. - The study involved 100 participants, with the OSA group showing significantly narrower transverse intermolar distance and higher palatal height compared to controls, demonstrating a strong association (p<0.001) between these parameters and OSA severity [4]. Treatment Efficacy - Vivos-trained providers have successfully treated tens of thousands of OSA patients using Vivos CARE devices, with many patients completing treatment in less than 12 months and experiencing little to no remaining OSA symptoms [2]. - The unique mechanism of action in Vivos CARE devices allows for gradual redevelopment and repositioning of dental arches and jaws, potentially leading to lasting results [5]. Market Context - OSA affects over 1 billion people globally, with 80% remaining undiagnosed. The condition is linked to various chronic health issues, and traditional treatments like CPAP often fail to address root causes [10]. - The company estimates that several million Americans will undergo sleep tests this year, with nearly half likely to test positive for OSA, highlighting a significant market opportunity for Vivos devices [8].